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Introduction
Delayed puberty and decreased final length is reported in
chronic diseases like Crohn’s disease and JIA with a dis-
ease onset at prepubertal age. This may be due to systemic
effects of inflammation, undernutrition or medication, for
example glucocorticoids or MTX. Treatment with anti
TNF has shown to restore delayed growth in JIA.
Objectives
To describe growth, onset and progression of puberty in
established JIA patients who are treated intensively.
Methods
All consecutive JIA patients aged 10-24 years were asked
to participate in this observational follow-up study.
Demographic and disease related items were obtained
yearly as well as Tanner puberty stages: Pubic Hair Girls
(PHG), Breast stage (Bre), Menarche (Men), Pubic Hair
Boys (PHB), Genital Stage (Gen). Reference Values were
obtained from the Dutch National Growth Study. Median
age at reaching each pubertal stage was estimated by
Kaplan Meier survival estimates based on the data from
patients of Caucasian origin and younger than 21 years.
Non parametric tests are used to determine significant
differences.
Results
118 girls (67%) and 58 boys (33%) entered the study.
Thirteen percent have systemic onset type of JIA, 24%
oligo- persistent type, 54% oligo-extended and polyarticular
type and 9% other subtypes of JIA.
Median disease duration is 8.5 years (IQR 7,3). Median
JADAS 27 is 3,8 (IQR 6.9), active joint count is 0,0 (2.0),
DAS 28 is 2,18 (1,37). MTX is ever or currently used in
78% of the patients, anti TNF in 15% and systemic corti-
costeroids in 24%. Early disease onset before the age of
8 years is present in 59% of the patients. Eleven patients
are of non-Caucasian origin and 19 patients are older than
21 years, and are excluded from growth and puberty ana-
lysis. Median SDS length is -0,29 (IQR 1,38), SDS weight
-0,27 (1,46), SDS BMI -0,08 (1.71). PHG, Bre, PHB and
Gen are delayed in all stages 2-5, more pronounced in
stage 5. Median delay in PHG stage 5 is 3,4 years, Bre
stage 5 3,4 years, Menarche 3,5 years, PHB stage 5
1.6 years and Gen stage 5 1.7 years. Progression of puberty
is more delayed in stage 4 and 5 compared to healthy
Dutch children. No significant differences are seen
between users and non-users of systemic corticosteroids,
MTX or anti TNF. Subtype of JIA, disease activity and age
at onset of JIA did not significantly influence results.
Conclusion
Although disease activity is low due to intensive treatment,
puberty is still remarkably delayed. Further investigation in
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